A delayed clinical trial actually boosted Bristol Myers Squibb's stock. Here's why.

Core Viewpoint - Bristol Myers' stock experienced a rally as investors remain optimistic about Cobenfy as a potential Alzheimer's treatment, despite a delay in the outcome of a late-stage trial [1] Group 1 - Investors are maintaining high hopes for Cobenfy, indicating strong market interest and potential for future growth in the Alzheimer's treatment sector [1] - The delay in the late-stage trial outcome has not significantly dampened investor sentiment, suggesting confidence in the drug's prospects [1]